The high cost of medicines in Ireland. Is it time to change the pricing mechanism?

European Journal of Health Economics

Volumn 5, Issue 4, 2004, Pages 341-344

  Tilson, Lesley ^a,c   McGowan, Bernadette ^a   Bennett, Kathleen ^b   Barry, Michael ^a  

^a Natl Centre for Pharmacoeconomics   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

Drug costs; European comparison; Ireland; Medicines

Indexed keywords

ARTICLE; COMPARATIVE STUDY; COST CONTROL; DRUG COST; EUROPE; IRELAND; MEDICAL INFORMATION; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; COST; DRUG INDUSTRY; ECONOMICS; FEE; PHARMACOECONOMICS; PUBLIC HEALTH; REIMBURSEMENT;

COST CONTROL; COSTS AND COST ANALYSIS; DRUG COSTS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; FEES, PHARMACEUTICAL; IRELAND; NATIONAL HEALTH PROGRAMS; RATE SETTING AND REVIEW; REIMBURSEMENT MECHANISMS;

EID: 17444362605     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-004-0245-2     Document Type: Article

References (24)

1. Kanavos P (2002) Pharmaceutical pricing and reimbursement in Europe. In: Scrip reports, regulatory affairs report series: PJB. pp 37-39
2. Department of Health and Children (1993) Agreement between the Federation of Irish Chemical Industries and the Department of Health on supply terms, conditions and prices of medicines supplied to the health services
3. Brennan N et al. (2003) Commission on Financial Management and Control Systems in the Health Service. Department of Health and Children. Available at: http://www.doh.ie
4. Deloitte & Touche in conjunction with the York Health Economics Consortium (2001) Value for money audit of the Irish health system. Department of Health and Children. Available at: http:// www.doh.ie
5. Martikainen J, Kivi I, Linnosmaa I (2004) European prices of newly launched reimbursable pharmaceuticals - a pilot study. Submitted to Health Policy
6. Folino-Gallo P, Walley T, Frolich JC, Carvajal A, Edwards IR (2001) Availability of medicines in the European Union: results from the Euro-Medicines project. Eur J Clin Pharmacol 57:441-446
7. Euro-Med Stat Group (2003) Monitoring expenditure and utilisation of medicinal products in the European Union countries: a Public Health approach. Eur J Public Health 13:1-6
8. Bryan J (2004) Will new deal lead to lower drug prices? Pharm J 272:568
9. Anonymous (2001) Guide to European pharmaceutical pricing and reimbursement systems. Urch Publishing Ltd, pp 36-180
10. Euro-Med Stat Group (2003) Working Group on Prices.http://www. euromedstat.cnr.it
11. Gross D (2003) Prescription drug prices in Canada. Public Policy Institute, AARP, pp 1-22
12. Danzon PM, Kim JD (1998) International price comparisons for pharmaceutical: measurement and policy issues. Pharmacoeconomics 14:115-128
13. Tilson L et al. (2001) Generic drug utilisation on the general medical services scheme in 2001. Irish Med J 96:176-179
14. Andersson F (1993) Methodological aspects of international drug price comparisons. Pharmacoeconomics 4:247-256
15. Danzon PM (1999) Price comparisons for pharmaceuticals: a review of US and cross-national studies. Wharton School, University of Pennsylvania:- Washington
16. Danzon PM, Furukawa MF (2003) Prices and availaibility of pharmaceutical: evidence from nine countries. Health Affairs W3:521-536
17. Martikainen J, Rajaniemi S (2002) Drug reimbursement systems in EU Member States, Iceland and Norway. Helsinki. Social Insurance Institution: Finland
18. Bronner M (2004) Study sheds light on Swiss price levels. Pharma Pricing and Reimbursement 9:4-7
19. Haga A, Sverre JM (2002) Pricing and reimbursement of pharmaceutical in Norway. Eur J Health Econ 3:215-220
20. Anonymous (2003) Pricing and reimbursement of medicinal products in Denmark. Ministry of the Interior and Health: Denmark
21. National Centre for Pharmaceoeconomics (2001) Estimated annual savings from generic substitution. Available at: http://www.ncpe.ie
22. Anonymous (2002) G10 medicines report. High level group on innovation and provision of medicines. Available at: http://pharmacos.eudra.org/F3/g10/ g10home.htm
23. Anonymous (2004) Strong language on G10 pricing at EFPIA meeting. Scrip 2915:4
24. Towse A (1998) The pros and cons of a single "Europrice" for drugs. Pharmacoeconomics 13:271-276